CTLA4 and cancer: Since 2000, immune checkpoint inhibitors such as ipilimumab and tremelimumab, CTLA-4 inhibitors that are used in a new and effective treatment strategy for immunotherapy in cancer, have been in clinical development (Chang et al., 2019).